

NEW ZEALAND DATA SHEET

1 PRODUCT NAME

Zoster Immunoglobulin-VF 200 IU, solution for intramuscular injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Human Zoster Immunoglobulin

Zoster Immunoglobulin-VF is a sterile solution containing 160 mg/mL human plasma protein of which at least 98% is immunoglobulin G (IgG) with antibodies to varicella-zoster virus of at least 200 IU/vial.

Zoster Immunoglobulin-VF contains less than 0.5 mg/mL immunoglobulin A (IgA).

Zoster Immunoglobulin-VF is manufactured from human plasma donated by New Zealand's voluntary and non-remunerated donors.

Zoster Immunoglobulin-VF contains 22.5 mg/mL of glycine.

Zoster Immunoglobulin-VF contains no preservatives.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Solution for intramuscular injection.

The pH value of the ready-to-use solution is 6.6.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Zoster Immunoglobulin-VF is indicated for prophylaxis against varicella in patients who meet all four of the criteria listed below:

1. One of the following underlying illnesses or conditions:
 - a. Neoplastic disease (leukaemia or lymphoma).
 - b. Congenital or acquired immunodeficiency.
 - c. Immunosuppressive therapy with steroids or antimetabolites.
2. One of the following types of exposure to chickenpox or shingles patients:
 - a. Household contact.
 - b. Playmate contact (>1 hour play indoors).
 - c. Hospital contact (in same 2 to 4 bedroom or adjacent beds in a large ward).
 - d. Newborn contact (newborn of mother who had onset of chickenpox <5 days before delivery or within 48 hours after delivery).
 - e. Premature infant (≥ 28 weeks gestation) whose mother lacks a prior history of chickenpox.
 - f. Premature infant (<28 weeks gestation or ≤ 1000 g) regardless of maternal history.

NEW ZEALAND DATA SHEET

3. Negative or unknown prior history of chickenpox.
4. If Zoster Immunoglobulin-VF can be administered within 96 hours after exposure.

Zoster Immunoglobulin-VF, Normal Immunoglobulin-VF (immunoglobulin for intramuscular use) or plasma are of no value in the treatment of established varicella or zoster infection. High levels of circulating antibody do not prevent dissemination of infection.

Zoster Immunoglobulin-VF is not indicated for prophylactic use in immunodeficient children or adults when there is a history of varicella, unless the patient's immunosuppressed status is that which is associated with bone marrow transplantation.

4.2 Dose and method of administration

Dose

The following dose schedule is recommended for Zoster Immunoglobulin-VF administration:

Dose of Zoster Immunoglobulin-VF based on body weight		
Weight of patient (kg)	Dose (IU)	No. of vials
0–10	125	1
10.1–20	250	2
20.1–30	375	2
30.1–40	500	3
over 40	600	3

Method of administration

Zoster Immunoglobulin-VF should be brought to room temperature before use, and given slowly by deep intramuscular injection using an appropriate sized needle. If a large dose is required, it is advisable to administer it in divided doses at different sites. This applies in the case of doses above 2 mL for children up to 20 kg body weight and doses above 5 mL for persons above 20 kg body weight.

Hyaluronidase and/or a suitable local anaesthetic may be added to the injection if desired.

For further instructions, see section 6.6.

4.3 Contraindications

Zoster Immunoglobulin-VF is contraindicated in patients:

- who have had a true anaphylactic reaction to the active substance or to any of the components of the product
- with immunoglobulin A (IgA) deficiency, unless they have been tested and shown not to have circulating anti-IgA antibodies, since these patients may experience severe reactions to the IgA which is present in trace amounts

NEW ZEALAND DATA SHEET

- who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.

4.4 Special warnings and precautions for use

Route of administration

Zoster Immunoglobulin-VF **MUST NOT be administered intravenously** because of the potential for anaphylactic reactions. Injections must be made intramuscularly, and care should be taken to draw back on the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel.

Hypersensitivity

Zoster Immunoglobulin-VF contains trace amounts of IgA which may provoke anaphylaxis in patients with anti-IgA antibodies, such as those with IgA deficiency.

Zoster Immunoglobulin-VF should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Rarely, human zoster immunoglobulin can induce a precipitous fall in blood pressure with anaphylactic reaction, even in patients who had tolerated previous treatment with human zoster immunoglobulin. In case of anaphylactic reaction, the treatment should be stopped immediately.

In the case of shock, treatment should follow the guidelines of shock therapy.

Patients should be observed for at least 20 minutes after administration of Zoster Immunoglobulin-VF. Particularly in cases of inadvertent intravenous injection, patients should be observed for longer term (at least 1 hour) after administration.

Pathogen safety

This product is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and theoretically Creutzfeldt-Jakob Disease (CJD) agents, that can cause disease.

The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents and by testing for the presence of certain viral markers.

In addition, virus removal and inactivation procedures are included in the manufacturing process. The current procedures applied in the manufacture of this product are effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV), and the non-enveloped viruses, such as hepatitis A virus (HAV) and human parvovirus B19.

There is no evidence to date that parvovirus B19 can be transmitted by Zoster Immunoglobulin-VF and the nanofiltration step of the manufacturing process has been shown to remove such viruses (or viruses of similar size). The product is known to contain antibodies to the virus.

NEW ZEALAND DATA SHEET

Despite these measures, such products may still potentially transmit disease. There is also the possibility that other known or unknown infectious agents may be present in such products.

Vaccination for patients in receipt of medicinal products from human plasma should be considered where appropriate.

It is strongly recommended that every time that Zoster Immunoglobulin-VF is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.

Genotoxicity and carcinogenicity

No genotoxicity, carcinogenicity or reproductive toxicity studies have been conducted with Zoster Immunoglobulin-VF. There have been no reports of such effects associated with the use of CSL Behring's plasma-derived products.

Effects on laboratory tests

After injection of immunoglobulin the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing. Passive transmission of antibodies to erythrocyte antigens (e.g., anti-A, anti-B, anti-D) may interfere with some serological tests for red cell allo-antibodies (e.g. Coombs' test).

4.5 Interaction with other medicines and other forms of interaction

Zoster Immunoglobulin-VF should not be mixed with other pharmaceutical products, except as indicated (see section 4.2).

Vaccinations with live attenuated virus vaccines

Passively acquired antibody can interfere with the response to live, attenuated virus vaccines. Therefore, administration of such vaccines, e.g. poliomyelitis or measles, should be deferred until approximately three months after passive immunisation. In the case of measles, the decrease in efficacy may persist for up to one year. Therefore, patients receiving measles vaccine should have their antibody status checked. If Zoster Immunoglobulin-VF is administered within two weeks of vaccination with a live attenuated virus vaccine, the efficacy of the vaccine may be compromised. Consideration should be given to re-vaccination approximately three months after Zoster Immunoglobulin-VF was given.

4.6 Fertility, pregnancy and lactation

The safety of this medical product for use in human pregnancy or during lactation has not been established in controlled clinical trials. Zoster Immunoglobulin-VF should therefore only be given with caution to pregnant women and breast-feeding mothers. Immunoglobulins are excreted in breast milk, however, it is not known whether this applies to passively administered Zoster Immunoglobulin-VF.

4.7 Effects on ability to drive and use machines

No effects on ability to drive and use machines have been observed.

NEW ZEALAND DATA SHEET

4.8 Undesirable effects

Summary of the safety profile

Local tenderness, erythema and stiffness may occur at the site of injection and may persist for several hours. This may occur after any intramuscular injection.

Angioedema, mild pyrexia, malaise, drowsiness and urticaria have been reported occasionally after injections of immunoglobulins. True allergic responses are rare. Skin lesions, headache, dizziness, nausea, generalised hypersensitivity reactions and convulsions have been reported on rare occasions.

Clinical studies

In the clinical trial with Hepatitis B Immunoglobulin, the following general and local reactions were recorded in the 58 healthy subjects (total number of events, up to and including 7 days post injection; pasteurised/unpasteurised product): malaise (20/22 events), drowsiness (13/17 events), induration (10/4 events), sensation of fever (4/4 events), chills (3/3 events), sweating (3/1 events) and warmth/heat when touched (0/4 events). There was an overall higher reporting of local tolerance adverse events at the injection site for the unpasteurised product, such as pain (32/52 events), bruising (10/22 events), redness (2/8 events) and irritation (2/4 events).

Paediatric population

The use of this product in the paediatric population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL Behring's intramuscular immunoglobulin products.

Elderly population

The use of this product in the elderly population has not been established in appropriate studies. To date, this population is not over-represented in spontaneous reports of adverse events associated with the use of CSL Behring's intramuscular immunoglobulin products.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

The consequences of overdosage are not known.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: immune sera and immunoglobulins, human varicella/zoster immunoglobulin.

NEW ZEALAND DATA SHEET

ATC code: J06BB03

Zoster Immunoglobulin-VF is manufactured from plasma donated by New Zealand's voluntary donors who have recently recovered from shingles or chickenpox. Donations are selected on the basis that they contain high levels of antibodies against *Herpesvirus varicellae*. Immunoglobulins for intramuscular injection, prepared by this process from plasma screened by current methods, have not been implicated in the transmission of viral infectious diseases including human immunodeficiency virus (HIV).

Studies using plasma spiked with HIV have shown that the Cohn cold-ethanol fractionation process produces a very large reduction in virus titre with undetectable levels in the immunoglobulin fraction. Epidemiological studies have not recognised any cluster of AIDS patients or HIV seroconversion in immunoglobulin recipients. The manufacturing process for Zoster Immunoglobulin-VF contains specific steps to reduce the possibility of viral transmission including pasteurisation for viral inactivation and nanofiltration for virus removal.

Mechanism of action

Zoster Immunoglobulin-VF contains high levels of antibodies (mainly IgG) against the varicella-zoster virus.

Zoster Immunoglobulin-VF has been shown to prevent varicella in susceptible contacts of an index case, and has been used successfully to prevent the spread of this infection in high-risk patients. Greatest effectiveness is to be expected when treatment commences within 96 hours of exposure; treatment after 96 hours is of uncertain value. High-risk patients are those with an immune deficiency or who are on immunosuppressive therapy.

Clinical efficacy and safety

A clinical trial with Zoster Immunoglobulin-VF has not been conducted.

A comparative clinical trial was conducted to investigate the effect of pasteurisation on the *in vivo* behaviour of intramuscular immunoglobulins using Hepatitis B Immunoglobulin (pasteurised and unpasteurised) as the representative of this group of products.

Fifty-eight (58) healthy subjects (28 males and 30 females) each received an intramuscular injection of pasteurised (viral inactivated) or unpasteurised Hepatitis B Immunoglobulin. No significant clinical differences were observed.

Twenty-eight (28) subjects received the viral inactivated product. Maximal serum concentration of IgG was reached after 8.0 ± 5.5 days (mean \pm s.d.), and the estimated half-life of IgG was 27.2 ± 6.6 days (mean \pm s.d.). These values are consistent with ranges observed with other intramuscular immunoglobulin products.

NEW ZEALAND DATA SHEET

5.2 Pharmacokinetic properties

Absorption and Distribution

The immunoglobulin after intramuscular administration is slowly absorbed into the recipient's circulation and reaches a maximum after a delay of 2 to 3 days. Human varicella immunoglobulin has a half-life of about 3 to 4 weeks. This half-life may vary from patient to patient.

Elimination

IgG and IgG-complexes are broken down in cells of the reticuloendothelial system.

5.3 Preclinical safety data

Zoster Immunoglobulin-VF contains varicella immunoglobulin as the active ingredient which is derived from human plasma and acts like an endogenous constituent of plasma. Single dose intramuscular application of immunoglobulin to various animal species did not reveal toxic effects.

Preclinical studies with repeated dose applications (chronic toxicity and carcinogenicity) cannot be reasonably performed in conventional animal models due to the development of antibodies following the application of heterologous human protein.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Glycine

Water for injections

6.2 Incompatibilities

This medicine must not be mixed with other medicines, diluents, or solvents except those mentioned in section 4.2.

6.3 Shelf life

3 years

Shelf life after first opening:

The product does not contain an antimicrobial preservative. It must, therefore, be used immediately after opening the vial.

6.4 Special precautions for storage

Store at 2°C to 8°C (Refrigerate. Do not freeze).

Protect from light.

For storage conditions of the medicine after first opening, see section 6.3.

6.5 Nature and contents of container

Solution in a single glass vial, with a rubber stopper, an aluminium seal and a plastic flip-top cap.

NEW ZEALAND DATA SHEET

Pack size

1 vial with 200 IU varicella-zoster antibody

The actual volume in the vial is stated on the label.

Zoster Immunoglobulin-VF is packaged in latex free materials.

Note: Supplies of suitable plasma for Zoster Immunoglobulin-VF production are scarce. Healthy adults recovering from shingles or chickenpox should be urged to enrol as voluntary blood donors.

6.6 Special precautions for disposal and other handling

Zoster Immunoglobulin-VF is a sterile, ready-to-use solution.

If the product appears to be turbid by transmitted light or contains any sediment it must not be used.

Any unused solution must be discarded appropriately.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

CSL Behring (NZ) Ltd

PO Box 62590

Greenlane

Auckland 1546

New Zealand

For Medical/Technical Enquiries: TOLL FREE: 0800 640 677

For Customer Service Enquiries: TOLL FREE: 0800 841 532

customerservice@cslobehring.com.au

www.cslobehring.com.au

Manufacturer

CSL Behring (Australia) Pty Ltd

189–209 Camp Road

Broadmeadows VIC 3047

Australia

NEW ZEALAND DATA SHEET

Distributor

New Zealand Blood Service
71 Great South Road
Epsom
Auckland
New Zealand

9 DATE OF FIRST APPROVAL

9 July 1992

10 DATE OF REVISION OF THE TEXT

8 June 2022

SUMMARY TABLE OF CHANGES

Section changed	Summary of new information
2	Addition of immunoglobulin A value.